Reuters logo
2 months ago
BRIEF-Morphosys presents data from phase 2 clinical trial with MOR208 in patients with DLBCL
June 5, 2017 / 1:06 PM / 2 months ago

BRIEF-Morphosys presents data from phase 2 clinical trial with MOR208 in patients with DLBCL

1 Min Read

June 5 (Reuters) - MORPHOSYS AG:

* MORPHOSYS PRESENTS FIRST SAFETY AND EFFICACY DATA OF MOR208 IN COMBINATION WITH LENALIDOMIDE FROM A PHASE 2 STUDY IN DLBCL

* PRELIMINARY DATA SHOW AN OBJECTIVE RESPONSE IN 19 OUT OF 34 PATIENTS (ORR: 56%).

* COMPLETE REMISSION WAS SEEN IN 11 OUT OF 34 PATIENTS (CR: 32%). 16 OUT OF 19 PATIENTS IN WHOM RESPONSES WERE RECORDED, WERE STILL ON STUDY AT TIME OF DATA-CUT OFF Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below